The data will be presented at the Biomarkers & Diagnostics World Congress in Philadelphia, May 16-19, 2016

FOSTER CITY, CA, UNITED STATES, May 12, 2016 /EINPresswire.com/ -- MedGenome provides customized genomic solutions in cancer immunotherapy to enable pharma and biotech companies develop superior biomarkers will present an abstract titled “Somatic Mutations Influence Infiltration of T-Cells in Human Cancers” at the Biomarkers and Diagnostics World Congress, being held at Marriott Downtown, Philadelphia, from May 16-19, 2016.

Tumor cells employ a variety of immune-evasive mechanisms to protect themselves from immune attack, mediated through inhibition of T-cell infiltration, avoiding recognition by T-cells, and by creating an immune suppressive microenvironment to paralyze an immune attack. The mechanisms contributing to T-cell infiltration within the tumor is poorly characterized. Most studies have focused on tumor extrinsic factors produced by stromal cells and tumor associated macrophages that actively block T-cells from entering the tumors. We know very little of the tumor-intrinsic mechanisms that prevent T-cells from infiltrating into the tumor microenvironment. MedGenome’s proprietary genomic solution OncoPeptTUME takes an unbiased approach to identify T-cell enriched or T-cell depleted tumors using T-cell-specific gene signatures. A combined analysis of gene expression and mutational burden identified differentially regulated pathways in these T-cell inflamed or depleted tumors.

This study demonstrates that tumor cell-intrinsic genetic alterations modulate signalling pathways that directly impact T-cell infiltration through factors that alter the tumor microenvironment. OncoPeptTUME provides a holistic view of the tumor microenvironment to immune-oncology researchers to discover new therapeutic targets and biomarkers.

About MedGenome

MedGenome (http://www.medgenome.com) is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Its unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized health care. MedGenome is a market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally.

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
MedGenome
7022020883
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.